Targeting CD4+CD28- T cells by blocking CD28 co-stimulation

Trends in Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 1-2

  Airò, Paolo ^a   Scarsi, Mirko ^a  

^a Rheumatology and Clinical Immunology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

CD4+ T LYMPHOCYTE; CELL EXPANSION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DRUG EFFECT; HUMAN; IN VITRO STUDY; IN VIVO GENE TRANSFER; LETTER; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ANTIGENS, CD28; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNE SYSTEM DISEASES;

EID: 84871712547     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.10.013     Document Type: Letter

References (10)

1. - T cells in immune disorders. Trends Mol. Med. 2012, 18:446-453.
2. Vallejo A.N., et al. T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection. Trends Mol. Med. 2004, 10:119-124.
3. Scarsi M., et al. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J. Rheumatol. 2010, 37:911-916.
4. Scarsi M., et al. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J. Rheumatol. 2011, 38:2105-2111.
5. Kremer J.M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 2003, 349:1907-1915.
6. Marti L., et al. Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann. N. Y. Acad. Sci. 2009, 1173:334-342.
7. Buch M.H., et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann. Rheum. Dis. 2009, 68:1220-1227.
8. Koenders M.I., et al. T cell lessons from the rheumatoid arthritis synovium SCID mouse model. CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization. Arthritis Rheum. 2012, 64:1762-1770.
9. Bryl E., et al. Down-regulation of CD28 expression by TNF-alpha. J. Immunol. 2001, 167:3231-3238.
10. Bryl E., et al. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum. 2005, 52:2996-3003.